Myriad Completes Acquisition of Sividon Diagnostics

Myriad Genetics has finalized its acquisition of Sividon Diagnostics, a breast cancer prognostic company, for approximately $39 million upfront.

Under the deal, Myriad will also gain $17 million in potential milestones. — Anisa Jibrell